Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.

Deghenghi R, Papotti M, Ghigo E, Muccioli G, Locatelli V

Endocrine1 Feb 2001Cited by 15 (Europe PMC)

PMID11322499DOI10.1385/endo:14:1:029PepBankPUB-11322499

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

01LabEx vivo tissueActivity measurement
In human pituitary tissue, GHRP‑2 displaced Tyr-Ala-hexarelin binding in a dose-dependent manner.
In plain wordsIn human pituitary tissue samples, GHRP‑2 competed with a labelled GHRP for its receptor.
Peptide
GHRP-2
Outcome
DecreaseDisplacement of Tyr-Ala-hexarelin binding
Study
humann: not reported in source
Human pituitary gland receptor binding
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Tyr-Ala-hexarelin binding was displaced in a dose-dependent manner by different GHRPs (hexarelin, GHRP-2, and EP-51216).
2 context sentences(design, population, supporting numbers)
Summary · context
The binding affinity of somatostatin-14 (SRIF), various SRIF derivatives, and some peptides belonging to the growth hormone-releasing peptide (GHRP) family to specific receptors for SRIF and GHRP in the human pituitary gland has been measured.
Summary · context
GHRP receptors have been identified using [125I]Tyr-Ala-hexarelin, a peptide that thas been demonstrated to be a potent growth hormone (GH) releaser in humans.
Report a problemFND-1132249901
02LabEx vivo tissueActivity measurement
In human pituitary tissue, hexarelin displaced Tyr-Ala-hexarelin binding in a dose-dependent manner.
In plain wordsIn human pituitary tissue samples, hexarelin competed with a labelled GHRP for its receptor.
Peptide
Hexarelin
Outcome
DecreaseDisplacement of Tyr-Ala-hexarelin binding
Study
humann: not reported in source
Human pituitary gland receptor binding
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Tyr-Ala-hexarelin binding was displaced in a dose-dependent manner by different GHRPs (hexarelin, GHRP-2, and EP-51216).
2 context sentences(design, population, supporting numbers)
Summary · context
The binding affinity of somatostatin-14 (SRIF), various SRIF derivatives, and some peptides belonging to the growth hormone-releasing peptide (GHRP) family to specific receptors for SRIF and GHRP in the human pituitary gland has been measured.
Summary · context
GHRP receptors have been identified using [125I]Tyr-Ala-hexarelin, a peptide that thas been demonstrated to be a potent growth hormone (GH) releaser in humans.
Report a problemFND-1132249902

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

03LabNot a test of GHRP-2 aloneEx vivo tissueActivity measurement
In human pituitary tissue, GHRPs as a group did not displace [125I]Tyr1-SRIF-14 binding.
In plain wordsIn human pituitary tissue samples, growth hormone-releasing peptides as a group did not compete for the somatostatin receptor.
Peptide
GHRP-2
Outcome
No significant changeDisplacement of [125I]Tyr1-SRIF-14 binding by GHRPs
Study
humann: not reported in source
Human pituitary gland receptor binding
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
When [125I]Tyr1-SRIF-14 was used as a ligand, we observed displacement with SRIF and the octapeptide SRIF analogs but not with GHRPs and other SRIF derivatives.
2 context sentences(design, population, supporting numbers)
Summary · context
The binding affinity of somatostatin-14 (SRIF), various SRIF derivatives, and some peptides belonging to the growth hormone-releasing peptide (GHRP) family to specific receptors for SRIF and GHRP in the human pituitary gland has been measured.
Summary · context
GHRP receptors have been identified using [125I]Tyr-Ala-hexarelin, a peptide that thas been demonstrated to be a potent growth hormone (GH) releaser in humans.
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1132249903
04LabNot a test of Hexarelin aloneEx vivo tissueActivity measurement
In human pituitary tissue, GHRPs as a group did not displace [125I]Tyr1-SRIF-14 binding.
In plain wordsIn human pituitary tissue samples, growth hormone-releasing peptides as a group did not compete for the somatostatin receptor.
Peptide
Hexarelin
Outcome
No significant changeDisplacement of [125I]Tyr1-SRIF-14 binding by GHRPs
Study
humann: not reported in source
Human pituitary gland receptor binding
Outcome group
Receptor activity and mechanism · Endocrine and hormones
Source sentences
Summary
When [125I]Tyr1-SRIF-14 was used as a ligand, we observed displacement with SRIF and the octapeptide SRIF analogs but not with GHRPs and other SRIF derivatives.
2 context sentences(design, population, supporting numbers)
Summary · context
The binding affinity of somatostatin-14 (SRIF), various SRIF derivatives, and some peptides belonging to the growth hormone-releasing peptide (GHRP) family to specific receptors for SRIF and GHRP in the human pituitary gland has been measured.
Summary · context
GHRP receptors have been identified using [125I]Tyr-Ala-hexarelin, a peptide that thas been demonstrated to be a potent growth hormone (GH) releaser in humans.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.
Report a problemFND-1132249904

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 5Current
27 Oct 2026, 16:36 UTC
The same notice was added 2 times, first on 27 Oct 2026, 16:36 UTC. The status did not change between them.
Study data updated · source update from Europe PMC
Version 3
13 Oct 2026, 21:44 UTC
Study results updated
Version 2
13 Oct 2026, 16:31 UTC
Study data updated · source update from Europe PMC
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.